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LETTER TO THE EDITOR Open Access
Mutational profiling of acute lymphoblastic
leukemia with testicular relapse
Ling-Wen Ding1*†, Qiao-Yang Sun1†, Anand Mayakonda1†, Kar-Tong Tan1, Wenwen Chien1,2, De-Chen Lin1,2,
Yan-Yi Jiang1, Liang Xu1, Manoj Garg1,3, Zhen-Tang Lao1,4, Michael Lill2, Henry Yang1, Allen Eng Juh Yeoh1,5*
and H. Phillip Koeffler1,2
Abstract
Relapsed acute lymphoblastic leukemia (ALL) is the leading cause of deaths of childhood cancer. Although relapse
usually happens in the bone marrow, extramedullary relapse occasionally occurs including either the central
nervous system or testis (<1–2%). We selected two pediatric ALL patients who experienced testicular relapse and
interrogated their leukemic cells with exome sequencing. The sequencing results and clonality analyses suggest
that relapse of patient D483 directly evolved from the leukemic clone at diagnosis which survived chemotherapy. In
contrast, relapse leukemia cells (both bone marrow and testis) of patient D727 were likely derived from a common
ancestral clone, and testicular relapse likely arose independently from the bone marrow relapsed leukemia. Our
findings decipher the mutational spectra and shed light on the clonal evolution of two cases of pediatric ALL with
testicular relapse. Presence of CREBBP/NT5C2 mutations suggests that a personalized therapeutic approach should
be applied to these two patients.
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To the editor
Relapsed acute lymphoblastic leukemia (ALL) is the
leading cause of deaths of childhood cancer [1–3]. Al-
though relapse usually occurs in the bone marrow (me-
dullary), extramedullary relapse occasionally occurs,
including either in the central nervous system or testis
(<1–2%). Involvement of these organs is often associated
with an inferior prognosis, perhaps because the blood-
brain/blood-testis barrier hinders efficient delivery of
chemotherapy, and/or the leukemic cells infiltrated in
these immune-privileged sites may escape efficient
immune surveillance. Currently, clonal origin and evolu-
tion of extramedullary relapse ALL remain poorly under-
stood. To address this, we selected two pediatric ALL
patients who experienced testicular relapse and interro-
gated their leukemic cells with exome sequencing (see
Additional file 2: Supplementary Methods).
Patient D483 (5.6 years old at diagnosis) was treated as
an intermediate-risk B-ALL [hyperdiploid:56,XY,+X,t
(2;14)(p?13;q32),+4,+8,+9,+10,+14,+17,+18,+21,+21, ab-
sence of any well-known leukemic fusion oncogene]. He
developed bone-marrow (96% blast) and testicular
relapse 5 years after induction of remission. Mutations
of KRAS (G12D) and CREBBP (S1436C, in histone-
acetyltransferase HAT domain) were found in the found-
ing leukemic clone at diagnosis and persisted in bone
marrow and testis at relapse (Additional file 1: Table S1).
CREBBP encodes a histone/non-histone acetyltransfer-
ases which is involved in regulation of glucocorticoid
gene expression, its mutation contributes to prednisol-
one/dexamethasone (glucocorticoid) resistance [4, 5].
Mutation and copy-number deletion of CREBBP are fre-
quent in B-cell lymphoma and ALL [3, 6] and are often
associated with disease relapse. A missense mutation
(R17Q) of MEF2B (MADS-box transcription enhancer
factor-2) was found in both the bone marrow and tes-
ticular relapse samples. Missense mutation of MEF2B is
frequently detected in diffuse large B-cell lymphoma and
contributes to malignant transformation by regulating
expression of the proto-oncogene BCL6 [7]. Other
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mutations included EVX1 (homeobox protein) and
OTUD5 (regulates p53 stability by deubiquitinating p53)
(Additional file 1: Table S1).
Second patient (case D727, 1.3 years old at diagnosis
of B-ALL) harbored a MLL-AF9 fusion gene [t(9;11)]
and was treated as a high-risk ALL (82.8% blast in per-
ipheral blood). MLL fusion is often associated with
infant-ALL and a poor prognosis. Complete remission
was achieved after induction therapy; however, the
patient relapsed (91% blast) after a 2.3-year remission.
NT5C2 gene (encodes a 5′-nucleotidase involved in
purine metabolism) had two mutations in the relapse
samples, differencing in their VAF in the bone marrow
(34%) and testicle (5%) for R367Q mutation; while
D407V mutation was present with a VAF of 7% in bone
marrow and 36% in testicular relapse. These two NT5C2
mutations occur as recurrent mutational hotspots in
relapse-ALL and they have been functionally validated
[8]. These mutations increase the NT5C2 inosine-5-
monophosphate-nucleotidase activity; and therefore lead
to resistance to one of the chemotherapeutic drugs, 6-
mercaptopurine [8, 9] (part of child’s treatment). Additional
mutations that occurred in this child’s ALL cells included
DUSP13 (phosphatase that regulates JNK/P38 phosphoryl-
ation), MAPK8 (JNK1), PPP1R3B (protein phosphatase 1
regulatory subunit 3B), and ALPK3 (alpha-kinase 3)
(Additional file 1: Table S1).
To gain insight into the evolutionary trajectories of these
two ALL cases, we analyzed mutational clustering of VAF
and clonal evolution based on their sequencing data (Add-
itional file 2: Supplementary Methods). Mutations shared at
leukemic diagnosis and relapse represent early mutations
Fig. 1 Clonal evolution of ALL in patient D483. a Venn diagram shows mutations that occurred at leukemic diagnosis, bone marrow relapse, and
testicular relapse in patient. b Cluster of mutations at initial marrow diagnosis, relapse of bone marrow, and testicle. c Clonal evolution lineage
tree and sample composition of case D483. Lineage tree was constructed based on the constraint network using LICHeE [10]. Each node (circle)
represents a sub-population of leukemic cells. Numbers inside circles indicate number of shared single nucleotide variants (SNVs, including synonymous
SNVs and filtered with outliers of mutation cluster), numbers outside the circles show the mean VAF of each cluster. Color in each sample indicates
mutational groups in that sub-population of cells, and the subdivision in a sample suggest potential mixed lineage pattern. GL germline, BM DX bone
marrow at diagnosis, BM REL bone marrow at relapse, TES REL relapse in the testis
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and constitute the founding clone, while mutations occur-
ring only at diagnosis in the marrow or only relapse sam-
ples of testicle/bone marrow likely were acquired later. For
patient D483, the relapse leukemia directly evolved from
the original leukemic clone at diagnosis; all mutations at
diagnosis were persistent (Fig. 1a), and four additional
missense-mutations [MEF2B (R17Q), KCNG1 (L252V),
AIM1 (G109R), and OTUD5 (G222D)] were acquired with
different VAF at relapse in both bone marrow and testis,
suggesting that both sites of relapse evolved from the same
leukemic clone at diagnosis (Fig. 1b, c). In contrast, patient
D727 had a proportion of mutations present at diagnosis
which were absent at relapse, suggesting that the relapsed
leukemia arose from an ancestral clone which existed be-
fore the overt leukemia at diagnosis. Analysis of mutational
pattern and VAF suggests that relapse in patient’s testicle
represents an independent subclone from the relapse in the
bone marrow, albeit they share a common progenitor clone
derived from the original ancestral clone (Fig. 2a–c). Of
note, a fraction of mutations present at diagnosis persisted
in the testicle but were absent in relapsed marrow, suggest-
ing that the relapse ALL evolved following a parallel
branching hierarchy instead of a linear acquisition path.
Additional files
Additional file 1: Table S1. Variant allele frequency (VAF) of somatic
mutations in both cases. (DOCX 24 kb)
Additional file 2: Supplementary Methods. (DOCX 14 kb)
Fig. 2 Clonal evolution of ALL in patient D727. a Venn diagram shows mutations that occurred at leukemic diagnosis and relapse of
bone-marrow and testicle in patient D727. b Cluster of mutations at diagnosis (DX), bone marrow relapse (REL), and testicular relapse
(TES). c Clonal evolution lineage tree and sample composition of case D727. Lineage tree was constructed based on constraint network
using LICHeE [10]. Each node (circle) represents a sub-population of leukemic cells. Numbers inside circles indicate number of shared SNVs
(including synonymous SNVs and filtered with outliers of mutation cluster), numbers outside circles show mean VAF of each cluster. Color
in each sample indicates mutational groups in that sub-population of cells, and subdivision in a sample suggest a potential mixed lineage
pattern. GL germline, BM DX bone marrow at diagnosis, BM REL bone marrow at relapse, TES REL relapse at testis
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